Key result
Short-term aspirin plus DOAC after pediatric surgical pulmonary valve replacement showed similar bleeding rates and valve function compared to aspirin alone.
Why the study?
Does short-term thromboprophylaxis with aspirin plus a direct oral anticoagulant improve pulmonary valve function or increase bleeding compared to aspirin monotherapy in children undergoing surgical bioprosthetic pulmonary valve replacement?
Cohort (n=66)
No
Does short-term thromboprophylaxis with aspirin plus a direct oral anticoagulant improve pulmonary valve function or increase bleeding compared to aspirin monotherapy in children undergoing surgical bioprosthetic pulmonary valve replacement?
In children undergoing surgical bioprosthetic pulmonary valve replacement, adding a DOAC to aspirin for 90 days showed a similar safety profile to aspirin alone but provided no short-term echocardiographic benefit in valve function.
Answers are grounded in this paper and cite their sources.
Short-term DOAC addition to ASA post-SPVR in children remains unproven; leaves open optimal thromboprophylaxis strategy.
The impact of short-term thromboprophylaxis on short and mid-term outcomes in children undergoing surgical pulmonary valve placement (SPVR) is not well defined. Furthermore, the use of direct oral anticoagulants (DOACs) in this population is not well studied. In this single-center, retrospective study, aspirin (ASA) monotherapy was compared to short-term (3 months) ASA + DOAC in children ≤ 18 years of age undergoing SPVR. We aimed to evaluate pulmonary valve (PV) mean gradient, PV peak gradient, and PV dysfunction (defined as moderate or greater regurgitation or stenosis) on echocardiogram at three time points: post-operative discharge (T1), one-year follow-up (T2), and most recent follow-up (T3). Sixty-six patients were included, of whom 32 received ASA monotherapy and 34 received ASA + DOAC for 90 days, with a total median follow-up time of 851 days. Baseline demographics were similar between the groups. There was no difference between groups regarding PV mean and peak gradient, or PV dysfunction at T1, T2, or T3. There were 16 bleeding events with no difference between the ASA and ASA + DOAC groups (6 (19%) vs. 10 (29%); p = 0.31, respectively). There were no differences regarding clinically relevant non-major bleeding, readmission within 30-days for bleeding, or hospital length of stay. In children undergoing SPVR, short-term thromboprophylaxis with ASA + DOAC had a similar safety profile to ASA monotherapy. DOAC use did not show significant benefit in PV function in the short-term. The benefits of DOAC thromboprophylaxis in SPVR should be evaluated with long-term, prospective studies.
No takes yet. Share an insight, caveat, or question.
Nguyen et al. (2026) conducted a cohort in Surgical bioprosthetic pulmonary valve replacement in children (n=66). Aspirin + Direct Oral Anticoagulant (DOAC) vs. Aspirin monotherapy was evaluated on Pulmonary valve mean gradient, peak gradient, PV dysfunction (moderate or greater regurgitation or stenosis), and bleeding events (p=0.31). Short-term aspirin plus DOAC after pediatric surgical pulmonary valve replacement showed similar bleeding rates and valve function compared to aspirin alone.
Synapse has enriched 10 related papers. Consider them for comparative context: